Received Date : 22-Jan-2016

Revised Date : 24-Mar-2016

Accepted Date : 17-Apr-2016

Article type : O - Original Article



# Clinical presentation and determinants of mortality of invasive pulmonary aspergillosis in kidney transplant recipients: a multinational cohort study

**Authors' names and affiliations:**

Francisco López-Medrano (1); Mario Fernández-Ruiz (1); José Tiago Silva (1); Peggy L. Carver (2); Christian van Delden (3); Esperanza Merino (4); María José Pérez-Saez (5) Milagros Montero (6); Julien Coussement (7); Milene de Abreu Mazzolin (8), Carlos Cervera (9); Lidia Santos (10); Nuria Sabé (11); Anne Scemla (12); Elisa Cordero (13); Leónidas Cruzado-Vega (14); Paloma Leticia Martín-Moreno (15); Óscar Len (16); Eddison Rudas (17); Alfredo Ponce de León (18); Mariano Arriola (19); Ricardo Lauzurica (20); Miruna David (21); Claudia González-Rico (22); Fernando Henríquez-Palop (23); Jesús Fortún (24); Marcio Nucci (25); Oriol Manuel (26); José Ramón Paño-Pardo (27); Miguel Montejo (28); Patricia Muñoz (29); Beatriz Sánchez-Sobrino (30); Auxiliadora Mazuecos (31); Julio Pascual (5); Juan Pablo Horcajada (6); Thanh Lecompte (3); Asunción Moreno (9); Jordi Carratalà (11); Marino Blanes (32); Domingo Hernández (17); María del Carmen Fariñas (22); Amado Andrés (34); José María Aguado (1); and the Spanish Network for Research in Infectious Diseases (REIPI), the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), the Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Swiss Transplant Cohort Study (STCS).

1. Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain
2. University of Michigan Health System, Ann Harbor, Michigan

3. Service of Infectious Diseases, Department of Medical Specialities, University Hospitals Geneva, Geneva, Switzerland
4. Unit of Infectious Diseases, Hospital Universitario General, Alicante, Spain
5. Department of Nephrology, Hospital del Mar, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
6. Department of Infectious Diseases, Hospital del Mar, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
7. Department of Nephrology, Dialysis and Kidney Transplantation, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
8. Division of Nephology, Department of Medicine, Universidade Federal de São Paulo-UNIFESP and Hospital do Rim e Hipertensão, Fundação Oswaldo Ramos, São Paulo, Brazil
9. Department of Infectious Diseases, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona, Spain
10. Unit of Renal Transplantation, Department of Urology and Kidney Transplantation, Coimbra Hospital and Universitary Centre, Coimbra, Portugal
11. Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut d´Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
12. Service de Néphrologie et Transplantation Adulte, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, RTRS Centaure, Paris, France
13. Unit of Infectious Diseases, Hospitales Universitarios “Vigen del Rocío”, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain
14. Department of Nephrology, Hospital Universitario “La Fe”, Valencia, Spain
15. Department of Nephrology, Clínica Universitaria de Navarra, Pamplona, Spain
16. Department of Infectious Diseases, Hospital Universitari Vall d’Hebrón, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
17. Department of Nephrology, Hospital Universitario “Carlos Haya”, Málaga, Spain
18. Department of Transplantation, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, México DF, México
19. Clínica de Nefrología, Urología y Enfermedades Cardiovasculares, Santa Fe, Argentina
20. Department of Nephrology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
21. Department of Microbiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
22. Department of Infectious Diseases, University Hospital “Marqués de Valdecilla”, Santander, Spain
23. Department of Nephrology, University Hospital “Doctor Negrín”, Las Palmas de Gran Canaria, Spain

24. Department of Infectious Diseases, University Hospital “Ramón y Cajal”, Madrid, Spain
25. Department of Internal Medicine, Hematology Service and Mycology Laboratory, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
26. Department of Infectious Diseases and Transplantation Center, University Hospital (CHUV) and University of Lausanne, Switzerland
27. Department of Internal Medicine, Hospital Universitario “La Paz”, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
28. Department of Infectious Diseases, Hospital Universitario Cruces, Barakaldo, Bilbao, Spain
29. Department of Microbiology and Infectious Diseases, Hospital General Universitario “Gregorio Marañón”, Madrid, Spain
30. Department of Nephrology, Hospital Universitario Puerta de Hierro-Majadahonda, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
31. Department of Nephrology, Hospital Universitario “Puerta del Mar”, Cádiz, Spain
32. Unit of Infectious Diseases, Hospital Universitario “La Fe”, Valencia, Spain
33. Department of Nephrology, Hospital Universitari Vall d’Hebrón, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
34. Department of Nephrology, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (i+12), Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain

This study was partially presented at the 53rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Denver, CO (September 9-12, 2013).

***Corresponding author:*** Francisco López-Medrano, MD, PhD, MSc. Unit of Infectious Diseases. Hospital Universitario "12 de Octubre". Centro de Actividades Ambulatorias, 2ª planta, bloque D. Avda. de Córdoba, s/n. Postal code 28041. Madrid, Spain. Phone: +34 913908000. Fax: +34 914695775. E-mail address: **flmedrano@yahoo.es**

**Running title:** Outcome of invasive aspergillosis after KT

**List of abbreviations**

| | |
|---|---|
| AmB-D: | amphotericin B deoxycholate |
| AmB-LC: | amphotericin B lipid complex |
| auROC: | area under the receiving operator characteristics curve |
| BAL: | bronchoalveolar lavage |
| CI: | confidence interval |
| CMV: | cytomegalovirus |

| | |
|---|---|
| COPD: | chronic obstructive pulmonary disease |
| CT: | computed tomography |
| eGFR: | estimated glomerular filtration rate |
| EORTC/MSG: | European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group |
| G-CSF: | granulocyte-colony stimulating factor |
| GM: | galactomannan |
| HBV: | hepatitis B virus |
| HCV: | hepatitis C virus |
| HR: | hazard ratio |
| HSCT: | hematopoietic stem cells transplantation |
| ICU: | intensive care unit |
| IFD: | invasive fungal disease |
| IPA: | invasive pulmonary aspergillosis |
| IQR: | interquartile range |
| KT: | kidney transplantation |
| L-AmB: | liposomal amphotericin B |
| OD: | optical density |
| SD: | standard deviation |
| SOT: | solid organ transplantation |

**Abstract**

The prognostic factors and optimal therapy for invasive pulmonary aspergillosis (IPA) after kidney transplantation (KT) remain poorly studied. We included in this multinational retrospective study 112 recipients diagnosed with probable (75.0% of cases) or proven (25.0%) IPA between 2000 and 2013. The median interval from transplantation to diagnosis was 230 days. Cough, fever and expectoration were the most common symptoms at presentation. Bilateral pulmonary involvement was observed in 63.6% of cases. Positivity rates for the galactomannan assay in serum and bronchoalveolar lavage samples were 61.3% and 57.1%. *Aspergillus fumigatus* was the most commonly identified species. Six- and 12-weeks survival rates were 68.8% and 60.7%, and 22.1% of survivors experienced graft loss. Occurrence of IPA within the first 6 months (hazard ratio [HR]: 2.29; *P*-value = 0.027) and bilateral involvement at diagnosis (HR: 3.00; *P*-value = 0.017) were independent predictors for 6-week all-cause mortality, whereas the initial use of a voriconazole-based regimen showed a protective effect (HR: 0.34; *P*-value = 0.007). The administration of antifungal combination therapy had no apparent impact on outcome. In conclusion, IPA entails a dismal prognosis among KT recipients. Maintaining a low clinical suspicion threshold is key to achieve a prompt diagnosis and to initiate voriconazole therapy.

## Introduction

Invasive pulmonary aspergillosis (IPA) constitutes a devastating complication that affects severely immunosuppressed patients. Subjects with hematological malignancies represent the subpopulation with the highest incidence and the worst prognosis among those prone to developing IPA (1). In addition, this life-threatening infection is also described in other groups of patients, as those with solid organ malignancies (1), chronic pulmonary diseases (2), admission to intensive care units (3) or solid organ transplantation (SOT) (4,5). Among this latter group, the highest incidence of IPA is described in lung transplant recipients, followed by heart and liver transplant recipients (4,6). The risk of IPA after kidney transplantation (KT) is relatively lower compared to those observed for other SOT populations, with incidence rates below 0.5% in most studies (6-8). Nevertheless, KT represents by far the most common transplant procedure. For example, more than 77,000 KT were performed worldwide in 2012 in comparison to 23,000 liver, 5,900 heart and 4,300 lung transplants (9). Therefore, KT recipients suffer from the highest burden of IPA events in absolute terms (8,10-12).

Despite this reality, our knowledge about the clinical presentation of IPA in KT recipients and its impact on patient and graft survival is scarce and mostly based on small case series (13) or studies including different SOT populations (11,14-17) or invasive fungal diseases (IFD) due to both molds and yeasts (18-20). Only one single-center case-control study (which included 41 cases of IPA) has specifically analyzed the determinants of outcome among KT recipients, although no details on clinical or radiological features were provided (21).

The generalization of use of anti-mold prophylaxis has markedly reduced the incidence of IFD among patients with hematological malignancies or hematopoietic stem cells transplantation (HSCT). This approach has been also extended to specific high-risk subgroups of liver and heart transplant recipients (4,22), although so far no formal recommendation has been made regarding the need for antifungal prophylaxis in KT recipients or the optimal targeted therapy once the diagnosis of post-transplant IPA has been established. Such a lack of evidence raises further concern in view of the high mortality rates (ranging from 39% to 61%) observed in previous studies (16,17,20,21).

Thus, additional information is urgently needed to better define the clinical picture of IPA in KT recipients and to gain insight into its determinants of outcome and best therapeutic approaches, with the ultimate aim of improving the dismal prognosis associated to this opportunistic infection. The present study was designed to collect detailed data derived from the joint effort of a multinational group in order to override the intrinsic limitation imposed by the limited number of patients with this complication that may be seen at a single institution.

## Patients and Methods

*Study design*

We performed a multinational retrospective cohort study in 29 hospitals located in Europe (Spain, Switzerland, Belgium, Portugal, France and United Kingdom) and the Americas (United States, Brazil, Mexico and Argentina). The Swiss Transplant Cohort Study contributed with the collective experience from 6 transplant centers in Switzerland (23,24). Participating centers were invited to include all the cases of proven or probable IPA diagnosed in KT recipients between January 1, 2000 and December 31, 2013. By using an standardized data collection form, anonymized information on demographic and baseline characteristics; post-transplant events; clinical, microbiological and radiological features of IPA; therapeutic approaches; and patient and graft outcome were collected for each case by local investigators and entered in a protected electronic database.

The *primary outcome* was all-cause mortality at 6 weeks from diagnosis. This outcome was chosen in line with recent clinical trials (25) due to its objective nature and close relatedness with IPA-attributable mortality (26). *Secondary outcomes* included all-cause mortality at 12 weeks from diagnosis and graft loss among those patients who survived beyond that point. The retrospective design of the study and the lack of homogeneity in terms of follow-up schedules after the initiation of antifungal therapy (i.e., timing of follow-up thoracic computed tomography [CT] scan) precluded us from selecting clinical and radiological response as study outcome.

This study was developed with the institutional support of the Spanish Network Research of Infectious Diseases (REIPI) and the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). The study protocol was approved by the Ethic Committee of the coordinating center as well as by the local Ethics Committees of the different participating centers, as required. The study was performed in accordance to the Helsinki Declaration and the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.

*Study definitions*

Post-transplant IPA was defined according to the criteria proposed in 2008 by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (27). We only included IPA cases that fulfilled modified EORTC/MSG definitions for probable or proven diagnosis categories. Cases were deemed as "proven IPA" when the diagnosis was established by the visualization of molds in a lung biopsy (or autopsy) with the simultaneous recovery of *Aspergillus* spp. in culture from lung biopsy, sputum, bronchoalveolar lavage (BAL) or bronchial brush samples. Cases were categorized as "probable IPA" on the basis of the simultaneous presence of at least one host factor plus a radiological criterion plus a mycological criterion. The host factor was assumed to be the receipt of KT under chronic immunosuppressive therapy. The modified radiological criteria included not only the demonstration of dense, well-circumscribed lesions (with or without halo sign or cavitation), but also other lung infiltrates compatible with infection. This latter criterion responds

to previous clinical experiences suggesting that IPA in SOT recipients may be accompanied by lung infiltrates (i.e., peribronchial consolidation or tree-in-bud pattern) that differ from the typical signs observed in hematological patients (6,28). The microbiological criteria included the recovery of *Aspergillus* spp. in culture from sputum, BAL or bronchial brush samples and/or a positive galactomannan (GM) assay (≥0.5 optical densities [OD] in plasma or serum specimens and ≥1.0 in BAL specimens). Imaging response in the follow-up CT scan was defined as complete (more than 90% radiographic improvement compared with baseline), partial (more than 50% radiographic improvement compared with baseline), stable (no change from baseline or less than 50% radiologic improvement) or failure (progression of disease). Mortality was assessed by review of medical chart records, institutional databases, regional or national transplant registries and their corresponding mortality information systems, as appropriate for each participating center. Mortality was considered to be "IPA-attributable" when the patient died with microbiological, histological or clinical evidence of active IPA and other potential causes of death could be excluded by the attending physician or the local site investigator. All cases were independently reviewed by an infectious disease specialist at the coordinating center. According to the interval between transplantation and diagnosis, cases of IPA were categorized as "early" (<180 days) or "late" forms (≥180 days). Given the long time frame of this study, an era effect was taken into account by dividing the cohort according to the date of diagnosis of IPA (2000-2006 and 2007-2013).

"Initial antifungal therapy" was that provided within the first two weeks of administration of systemic antifungal drugs with activity against *Aspergillus* for the episode of IPA. For the purpose of the present study, "active antifungal drugs" comprised the following classes: the different formulations of amphotericin B (amphotericin B deoxycholate [AmB-D], amphotericin B lipid complex [AmB-LC] or liposomal amphotericin B [L-AmB]), anti-mold triazoles (itraconazole [either as oral solution or capsules], voriconazole or posaconazole), and echinocandins (caspofungin, anidulafungin or micafungin). "Antifungal combination therapy" was defined as the concomitant use as initial therapy of two or more of these drugs for ≥72 hours within the first two weeks of therapy. A patient that was given two or more different drugs initiated at least two weeks apart was considered to have received monotherapy (categorized according to the first drug used). "Sequential therapy" was defined as the use of one systemic antifungal followed by its discontinuation and replacement with another drug (an overlap period of 48 hours or less was allowed), also within the first two weeks. For the purposes of multivariate analyses, patients receiving sequential therapy were classified according to the last drug used (providing it was administered for ≥50% of the overall length of therapy).

"Cytomegalovirus (CMV) disease" included viral syndrome and probable or definitive end-organ disease, as previously defined (29). The diagnosis of pneumonia included hospital-acquired, health-care associated and ventilator-associated forms. Only laboratory-confirmed cases of influenza were analyzed. "Delayed graft function" denoted the requirement for dialysis within the first two weeks after transplantation. "Acute graft rejection" was diagnosed by histological examination if possible or by response to empirical anti-rejection treatment (30). Estimated

glomerular filtration rate (eGFR) was assessed by the 4-variable Modification of Diet in Renal Disease (4-MDRD) equation (31). “Graft loss” was defined as the need for permanent return to dialysis and/or retransplantation.

*Statistical analysis*

Quantitative data were shown as the mean ± standard deviation (SD) or the median with interquartile ranges (IQR). Qualitative variables were expressed as absolute and relative frequencies. Categorical variables were compared using the $\chi^2$ test, whereas Student’s T test or U Mann-Whitney test were applied for continuous variables. Survival curves were estimated by the Kaplan-Meier method, and differences between groups were compared with the log-rank test. Univariate and multivariate Cox regression models were used to identify factors predicting all-cause mortality at 6 and 12 weeks, as well as graft loss among survivors. For the latter outcome, the week 12 after diagnosis of IPA was used as reference time point for survival analysis. Those variables found to be significant (*P*-value <0.05) at the univariate level were included into the multivariate models in a backward stepwise fashion. To estimate survival curves the date of diagnosis of IPA was set at the calendar day in which the first clinical sample yielding *Aspergillus* spp. or the first positive GM assay was obtained. Associations are expressed as hazards ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses were performed using a bootstrap approach to adjust the estimated HR for overfitting. Bootstrap validation estimates how good the performance of the prediction model obtained from the development set would be on a hypothetical set of new patients (32). To this aim, 200 bootstrap samples of equal size were generated from the study population by sampling with replacement.

A potential center effect on the primary study outcome was accounted for through the Cochran's and Mantel-Haenszel statistics by grouping participating centers according to two criteria: the center contributing the largest number of cases versus all other centers pooled, and those contributing less than 5 cases versus those contributing ≥5 cases.

To partially overcome the limitation posed by the non-randomized design of our study, and as a preliminary approach, we calculated the propensity for receiving antifungal combination therapy (versus monotherapy or sequential therapy) given the patient’s baseline characteristics and the clinical and radiological features of IPA at presentation. This score was estimated using a backward stepwise logistic regression model including variables with *P*-values <0.1 in the univariate analysis. In addition, and to increase the precision of the estimated exposure effect without increasing bias, we also adjusted the model for selected variables that were unrelated to the exposure (i.e., antifungal regimen), but significantly associated to the study outcome (6-week mortality). The fit of this model was assessed by means of the Hosmer-Lemeshow test and the area under the receiving operator characteristics curve (auROC). We then performed a 1:1 nearest neighbor matching on the propensity score with replacement and a caliper width of 0.25 to select two subgroups of patients (receiving combination therapy or other regimens) that were comparable in their pre-treatment characteristics (33).

All the significance tests were two-tailed. Statistical analysis was performed using SPSS version 15.0 (Statistical Package for Social Sciences Inc., Chicago, IL), graphics were generated with

Prism version 6.0 (GraphPad Software Inc., La Jolla, CA), and the propensity score matching was conducted using R version 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria).

## Results

*Study cohort*

We included 112 KT recipients from 33 different institutions (mean number of cases per center: 3.9 [range: 1-20]) (**Table S1** in Supplementary Material). According to the EORTC/MSG criteria there were 28 cases (25.0%) of proven IPA, whereas the remaining 84 (75.0%) were classified as probable (of which 21 [25.0%] received this diagnostic category on the basis of the abovementioned modified radiological criteria). Three-quarter of the cases occurred between 2007 and 2013. The median interval between transplantation and diagnosis was 230 days (IQR: 95.5-1117.8), with 51 (45.5%) and 61 cases (54.5%) occurring before and after the month 6 (early and late forms, respectively) (**Figure 1**). Two cases (1.8%) were diagnosed at autopsy. Six- and 12-week follow-up were achieved in 76 and 66 patients (which accounted for 98.7% [76/77] and 97.0% [66/68] of patients surviving at each of these points, respectively).

*Clinical presentation*

The baseline and transplant-related characteristics according to the timing of diagnosis are shown in **Table 1**. As compared to those with late IPA, recipients suffering from early forms had older donors, were receiving higher doses of corticosteroids and were more likely to be under tacrolimus-containing regimens at diagnosis, had been more frequently diagnosed with pneumonia, CMV disease, bloodstream infection and acute graft rejection during the three preceding months, and had been more commonly admitted into the intensive care unit (ICU) within that period.

**Table 2** details the clinical, radiological and microbiological features of IPA cases. Most of the patients presented with cough, fever and expectoration, and had multilobar involvement in the form of nodules in the CT scan, whereas extrapulmonary involvement was uncommon. Of note, 20 patients (18.0%) had no fever, expectoration or pleuritic chest pain at the time of diagnosis. We found no significant differences in clinical or radiological findings between early and late forms. Regarding the diagnostic procedures, patients with early IPA were more likely to undergo BAL in comparison to late cases. The positivity rates for the GM assay in serum and BAL samples were 61.3% (38/62) and 57.1% (12/21), respectively (60.0% [30/50] and 50.0% [9/18] when the analysis was restricted exclusively to probable cases). As expected, *A. fumigatus* was the most common species among the 99 episodes (88.4%) in which speciation was obtained.

*Therapeutic approaches and outcome*

One hundred and nine patients (97.3%) received some type of antifungal therapy with activity against *Aspergillus*. Therapy was initiated within the first 24 or 48 hours from diagnosis in most of the patients (67.0% [73/109] and 77.1% [84/109], respectively). The median duration of therapy was 42.5 days (IQR: 13-108-8). Voriconazole was the agent most commonly used in monotherapy (43.1% [47/109]), followed by L-AmB (9.2% [10/109]). Patients treated with L-AmB in monotherapy had poorer graft function at diagnosis of IPA than those receiving other regimens (baseline eGFR: 32.1 ± 20.0 versus 45.4 ± 33.7 mL/min/1.72 $m^2$; *P*-value = 0.037). On the other hand, patients that required ICU admission following diagnosis were also more

likely to be initially given L-AmB in monotherapy (22.7% [5/22] versus 5.7% [5/87]; *P*-value = 0.027). The median dose of L-AmB was 5.0 mg/Kg/day (range: 3-10). As shown in **Table 3**, 22 patients (20.1%) received antifungal combination therapy for a median period of 14 days, with voriconazole plus echinocandin (45.5% [10/22]) being the most common regimen. Sequential therapy was used in 16 patients (14.7%). Overall, there were no significant differences in therapeutic approaches according to the timing of diagnosis, except for the higher use of L-AmB in early IPA cases compared to late cases (16.3% [8/49] versus 3.3% [2/60], respectively; *P*-value = 0.019). Daily corticosteroid dose was reduced from baseline by ≥50% in 28.0% (21/109) of patients within the first month following diagnosis, particularly in cases of early IPA (40.0% [12/30] versus 20.0% [9/45]*; P*-value = 0.059).

Following the diagnosis of IPA, 22 patients (19.6%) required ICU admission for a median of 10.5 days (IQR: 3-23.5). A follow-up CT scan was performed in 64 patients (57.1%) after a median interval of 90 days (IQR: 46-197), and showed complete response in 35.9% of cases (23/64), partial response in 46.9% (30/64), stable disease in 9.4% (6/64) and failure in 7.8% (5/64). Six- and 12-weeks survival rates were 68.8% (95% CI: 59.7-76.6) and 60.7% (95% CI: 51.5-69.3), respectively. Most of the deaths at week 12 (75.0% [33/44]) were considered attributable to IPA, including 7 out of 9 cases that underwent autopsy. The median interval from diagnosis to death was significantly shorter for IPA-attributable mortality than for other causes (8.5 versus 38.5 days, respectively; *P*-value = 0.006). The 68 patients that survived beyond week 12 were additionally follow-up for a median of 638.5 days (IQR: 119-1474.5), and graft loss was reported in 15 of them (22.1%).

*Predictive factors for mortality*

**Table 4** shows the comparison between survivors and non-survivors at 6 weeks from diagnosis of IPA in terms of clinical characteristics and therapeutic approaches. By univariate analysis, it was found that survivors were more commonly diagnosed during the most recent study period (2007-2013) and treated with a voriconazole-based regimen. In contrast, non-survivors were more likely to have undergone invasive mechanical ventilation prior to diagnosis, to have early forms of IPA and bilateral pulmonary involvement, to receive combination therapy, and to require ICU admission and acute renal replacement therapy. The GM indexes in serum and BAL samples were also significantly higher compared to survivors.

The Cox regression model revealed that early IPA (HR: 2.29; 95% CI: 1.10-4.79; *P*-value = 0.027) and bilateral involvement (HR: 3.00; 95% CI: 1.22-7.39; *P*-value = 0.017) were independently associated with a higher mortality, whereas the use of a voriconazole-based regimen as initial therapy exerted a protective effect (HR: 0.34; 95% CI: 0.15-0.74; *P*-value = 0.007). Although the administration of combination therapy appears to increase the risk of mortality at the univariate level, such an effect did not remain in the multivariate model. The HRs and corresponding 95% CIs of the bootstrap resampling procedure based on 200 samples were similar to those obtained in the original model (data not shown). Survival rates at 6 weeks were significantly lower in patients with early IPA (56.0% versus 79.0%; log-rank *P*-value = 0.022) and in those receiving an antifungal regimen not based on voriconazole (55.0% versus

84.0%; log-rank *P*-value = 0.002) (**Figure 2**). The Cochran's and Mantel-Haenszel statistics did not find any evidence of center effect on these associations. In addition, their direction and magnitude remained essentially unchanged when analyses were restricted to proven cases, although lacking statistical significance due the low number of patients analyzed (data not shown).

As expected, patients that were given antifungal combination therapy significantly differed in terms of baseline characteristics and markers of disease severity in comparison to those treated with monotherapy or sequential regimens, including higher rates of pre-transplant dialysis, previous transplantation, chronic hepatitis C virus (HCV) infection and dyspnea and hemoptysis at presentation, higher number of lesions in the CT scan at diagnosis, and higher absolute neutrophil count at day 7, among others (**Table S2**). On the basis of these variables we estimated the propensity score for receiving antifungal combination therapy compared to monotherapy or sequential therapy. In addition, the timing of diagnosis (early versus late IPA) and the requirement for ICU admission at presentation were also entered into the model. The resulting score showed a good goodness-of-fit (Hosmer-Lemeshow test *P*-value = 0.794; auROC: 0.816; 95% CI: 0.698-0.935). There was an acceptable overlap between propensity scores for patients who were given one or other regimen, thus providing sufficient power for propensity adjustment in the survival analyses (**Figure S1**). Following assignment of propensity scores, each patient receiving combination therapy was matched to a single patient receiving monotherapy or sequential therapy who has the most similar estimated propensity score (i.e., the smallest distance). The lack of impact of combination therapy on the primary outcome was confirmed in this propensity-matched subanalysis (HR: 1.37; 95% CI: 0.43-4.31; *P*-value = 0.596).

The comparison between survivors and non-survivors at 12 weeks from diagnosis of IPA are shown in **Table S3**. Early occurrence of IPA (HR: 2.11; 95% CI: 1.01-4.09; *P*-value = 0.028), bilateral pulmonary involvement (HR: 2.49; 95% CI: 0.99-6.32; *P*-value = 0.053), and the requirement for ICU admission (HR: 2.24; 95% CI: 1.12-4.48; *P*-value = 0.023) and acute renal replacement therapy (HR: 2.00; 95% CI: 0.99-4.05; *P*-value = 0.054) were predictors of all-cause mortality at 12 weeks. Of note, the administration of combination therapy exerted a negative impact on this outcome (HR: 2.11; 95% CI: 1.04-4.29; *P*-value = 0.039), although such effect disappeared in the propensity-matched cohort (HR: 2.32; 95% CI: 0.80-6.69; *P*-value = 0.120). The presence of a positive HCV serostatus was identified as a risk factor at univariate but not multivariate analysis. Again, the bootstrap estimates of the multivariate HRs and 95% CIs were similar to those obtained from the original sample (data not shown).

Since the demonstration of bilateral lung involvement was identified to exert a negative impact on outcome, we further explored the factors associated to this condition at diagnosis. Patients with bilateral or unilateral infection did not significantly differ in terms of pre-transplant comorbidities, prior occurrence of acute graft rejection or CMV disease, or leukocyte or lymphocyte counts at diagnosis. On the other hand, dyspnea at presentation, higher number of nodules in the CT scan, presence of pleural effusion, and poorer graft function (as measured by

eGFR) were associated to bilateral involvement. In the multivariate logistic regression analysis the presence of dyspnea, number of nodules and graft function remained as independent predictor factors (**Table S4**).

*Predictive factors for graft loss*

Finally, we assessed the risk factors for the occurrence of graft loss among those patients that remained alive at 12 weeks from diagnosis of IPA (**Table S5**). The use of acute renal replacement therapy (HR: 16.89; 95% CI: 4.59 - 60.60; *P*-value <0.001) and the requirement for ICU admission, either within the 3 months prior to (HR: 4.24; 95% CI: 1.28 - 14.05; *P*-value = 0.018) or at the time of diagnosis (HR: 3.68; 95% CI: 1.04 - 12.99; *P*-value = 0.043) emerged as independent predictors, although it should be noted that the number of events analyzed was low (n = 15). The administration of any amphotericin B-containing regimen was identified as a risk factor at the univariate level but not after adjustment for potential confounders.

## Discussion

To our knowledge, the present study represents the largest cohort assessing the clinical characteristics and outcome of IPA among KT recipients and the first one to include detailed data on microbiological and radiological features. Some relevant clinical and prognostic information may be derived from our series. Firstly, IPA was found to be a devastating disease in the setting of KT, as 20% of the patients had to be admitted to the ICU following diagnosis, 31% had died at 6 weeks (43% if IPA occurred within the first 180 days after transplantation), and as much as 20% of survivors suffered from graft lost and required permanent return to dialysis or retransplantation.

It should be highlighted that almost half of the cases of IPA were diagnosed within the first 6 months after transplantation. Similar results have been communicated from previous smaller cohorts (21). Therefore, a low threshold for suspicion of this complication must be maintained throughout such period, particularly in view that the time interval to the onset of infection also exerted a relevant prognostic effect. Early cases of IPA had increased risk of death at 6 and 12 weeks, even after adjusting for a large range of potential confounders. The lack of obvious differences between early and late cases in variables reflecting disease severity (such as the number of nodules in CT scan or the requirement for ICU admission) or appropriateness of therapeutic approach suggests that the worse prognosis observed for the former would be primarily driven by host's factors. Indeed, subgroup comparisons suggest that patients diagnosed with IPA during the first 180 days had a greater immunosuppression (i.e., higher daily corticosteroid dose, previous occurrence of CMV disease or acute graft rejection) and poorer status (prior ICU admission) compared to those with later infection.

From a clinical perspective, it is noteworthy that about one-fifth of the patients presented with no typical symptoms of respiratory tract infection (fever, expectoration or pleuritic chest pain), and that a non-specific manifestation, such as cough, was the most commonly observed complain. With regards to the findings of the CT scan, the presence of cavitation or halo sign —classically deemed as specific signs of IPA, particularly in the hematological patient (34)— was reported in only one-third and one-fourth of the cases, respectively. In contrast, well-circumscribe nodules constituted the most common radiological sign (about 70% of cases), in line with previous studies (35). We found that bilateral pulmonary involvement acted as an independent predictor for all-cause mortality. A similar association has been reported in cancer patients (36). It seems plausible that the demonstration of bilateral infection may represent a surrogate marker for delayed diagnosis and advanced disease, a hypothesis further supported by the fact that we found no apparent differences in the net state of immunosuppression between patients with unilateral or bilateral involvement.

Our experience confirms that the more invasive is the diagnostic procedure, the greater is the possibility of achieving a microbiological confirmation to support the suspicion of IPA. Indeed, *Aspergillus* spp. was isolated in 18.2%, 31.8%, 58.5% and 85.0% of sputum, bronchial brush, BAL and lung biopsy samples, respectively. On the other hand, the GM assay was positive in about 60% of samples in which it was tested, suggesting an acceptable sensitivity, although the

design of our study did not allow us to assess the diagnostic performance of this biomarker. A previous meta-analysis reported a pooled sensitivity in SOT recipients sensibly lower (41%) (37). Heylen et al. observed in their single-center experience that the serum GM assay was positive in one-third of KT recipients (21), whereas a recent study obtained high sensitivity but low specificity values among liver transplant recipients (38). Interestingly, the GM indexes in both serum and BAL samples were significantly higher in non-survivors at 6 weeks compared to survivors, although we could not demonstrate the impact of this variable in the multivariate Cox model likely due to the limited number of patients in which the assay was performed. In line with this finding, Heylen et al. also reported that the height of the GM index (>2 ODs) acted as a risk factor for mortality in their experience (21). In view of this, we propose that the GM assay should be ordered in KT recipients with suspected post-transplant IPA not only on the grounds of its diagnostic value, but also due to its prognostic significance.

In relation to the therapeutic approaches, voriconazole monotherapy was administered as first-line treatment in more than 40% of the patients included in our multinational series, and its use was independently associated with a better outcome at 6 weeks. All-cause mortality was lower among cases diagnosed during the most recent study era (2007-2013), probably reflecting the increasing use of voriconazole (approved in 2002 (39)) over the recent years as well as overall improvements in post-transplant management. A similar trend has been observed for patients with heart (40) and liver (41) transplantation and hematological malignancies (36). Likewise, the positive impact of voriconazole-based regimens on mortality was also found in other high-risk populations, including HSCT recipients (16), patients with hematological malignancies (36), overall SOT recipients (16) and liver transplant recipients (41). Voriconazole acts as a potent inhibitor of cytochrome P450 isoform CYP2C19, which poses an increased potential for clinically relevant interactions with certain immunosuppressive drugs (42). This threat must be carefully taken in consideration whenever prescribing this antifungal agent in SOT recipients.

On the other hand, we found no significant association at the multivariate level between the use of voriconazole and 12-week mortality. Whereas it has been suggested that mortality at 6 weeks from diagnosis acts as a good surrogate for IPA-attributable mortality (26), later outcomes may be influenced to a greater extent by concurrent factors such as the loss of graft function or the severity of respiratory failure, even outweighing the protective role of antifungal therapy. In support of this, the requirement for ICU admission and renal replacement therapy following diagnosis emerged as independent risk factors for 12-week mortality. In that sense, voriconazole-based therapy remained significant in the multivariate analysis when both variables were removed from the Cox model (data not shown). Moreover, we cannot rule out that our study lacked statistical power to demonstrate differences in 12-week mortality according to the antifungal regimen. Interestingly, positive HCV serostatus exerted a negative impact on this outcome at the univariate level. Various studies have reported poorer patient and graft survival among HCV-positive KT recipients (43-45), and some of these series identified infectious complications as one of the leading causes of mortality (46), suggesting a reciprocal deleterious effect between HCV infection and the level of immunosuppression.

The initial use of antifungal combination therapy —mostly voriconazole plus echinocandin— was found to be related to poorer outcomes at the univariate level. However, the demonstration of imbalances in baseline and clinical characteristics suggests that this finding was likely subject to confounding by indication bias due to the observational design of our study, as further suggested by the lack of association observed in the propensity-matched cohort. Nevertheless, this subanalysis should be regarded as merely exploratory due to the low number of patients that were given combination regimens. The efficacy of the combination of voriconazole and an echinocandin as primary therapy for IPA remains controversial, with some retrospective studies suggesting a beneficial impact in SOT recipients compared to L-AmB monotherapy (47). A recent trial failed to demonstrate a clear benefit in patients with hematological malignancies or HSCT (25).

In contrast to other SOT populations, a distinctive issue concerning the clinical management of KT recipients that develop severe opportunistic infections lies on the possibility of performing a more intensive reduction of immunosuppression, even by assuming the risk of graft rejection and graft loss. Indeed, the overall amount of immunosuppression at the time of diagnosis of IPA was tapered in 80% of the cases analyzed. It is likely that such as high rate precluded us from demonstrating the potential role of this approach in terms of patient outcome.

A point of key interest in the setting of KT is the impact of post-transplant IPA on graft function and subsequent mortality. We observed that one-third of patients required acute renal replacement therapy at the time of diagnosis, and this factor was independently associated to all-cause mortality at 12 weeks. Renal failure is a well-described risk factor for poor outcome in HSCT recipients, patients with hematological o solid organ malignancies, and SOT recipients with IFD (5,16,36). Furthermore, more than 20% of survivors beyond week 12 developed graft loss, a complication that was more frequent among those requiring prior ICU admission and acute renal replacement therapy, as previously described for other SOT recipients (41). Although not achieving statistical significance in the multivariate model, we observed that the use of amphotericin B increased the risk of graft loss, thus emphasizing the role of voriconazole as first-line therapy not only on the grounds of better recipient survival, but also long-term graft function.

Certain limitations to our study should be noted, mostly derived from its retrospective design. Some clinical data could not be retrieved for all cases (i.e., follow-up imaging). As previously mentioned, the administration of antifungal combination therapy was not random but based on physician's criteria, and therefore particularly susceptible to confounding bias that cannot be completely removed through propensity score analysis. Moreover, these results should be interpreted with particular caution due to the reduced sample of the propensity-matched cohort. The prolonged inclusion period and the large number of participating centers, albeit strengthening the generalizability of our findings, entail some heterogeneity in terms of post-transplant and critical care practices. However, we have attempted to take into account this "era effect" when assessing determinants of outcome. Finally, and despite our study being the largest series exclusively focused on IPA after KT to date, the relatively low number of analyzed

events may limit the stability of the multivariate analysis, since it has been demonstrated that the results of Cox models suffers from increasing bias and variability, unreliable confidence interval coverage, and problems with model convergence as the ratio of events to predictor variables declines below 10 (48).

In summary, clinicians in charge of KT recipients must keep in mind the possibility of IPA in patients presenting with non-specific respiratory symptoms (such as cough), fever and nodular lung lesions, especially during the first months after transplantation. An aggressive diagnostic approach —which should includes GM testing in serum and BAL samples— and the prompt initiation of voriconazole-based therapy may be life-saving in this setting. Future studies are needed to better delineate the role of tapering immunosuppression in an attempt to improve the dismal prognosis of this opportunist infection without threatening the survival of the renal graft.

**Acknowledgments**

This research was supported by Plan Nacional de I+D+i and Instituto de Salud Carlos III (Proyecto Integrado de Excelencia [PIE] 13/00045), Subdirección General de Redes y Centros de Investigación Cooperativa, Spanish Ministry of Economy and Competitiveness, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015) - co-financed by European Development Regional Fund (EDRF) *"A way to achieve Europe"*. The study was also co-financed with an unrestricted grant from Pfizer Pharmaceutical (REI-ANT-2013-01). Mario Fernández-Ruiz holds a clinical research contract "Juan Rodés" (JR14/00036) from the Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness.

**Disclosure**

The authors of this manuscript have conflicts of interest to disclose as described by the *American Journal of Transplantation.* Francisco López-Medrano has been paid for talks on behalf of Pfizer, Gilead Sciences and Astellas Pharma. Mario Fernández-Ruiz has been paid for talks on behalf of Pfizer and Gilead Sciences. Peggy L. Carver has been paid for talks on behalf of MSD. Oscar Len has been paid for talks on behalf of Astellas Pharma and MSD and has received grants from MSD and Astellas. Oriol Manuel has received unrestricted grants for research from Roche and Lophius Bioscience. Mariano Arriola has been consultant for Novartis, Pfizer and Astellas Pharma. Jesús Fortún has received grant support from Astellas Pharma, Gilead Sciences, MSD, Pfizer and Instituto de Salud Carlos III. Ricardo Lauzurica has been paid for talks on behalf of Novartis and Astellas Pharma. Marino Blanes has been paid for talks on behalf of Astellas, Pfizer, Gilead and MSD. José María Aguado has been a consultant to and on the speakers' bureau for Astellas Pharma, Pfizer, Gilead, MSD and Roche. The other authors have no conflicts of interest to disclose as described by the *American Journal of Transplantation*.

## Figure legends

**Figure 1.** Temporal distribution of cases of invasive pulmonary aspergillosis occurring within the first 3 years after transplantation according to post-transplant month of diagnosis (light gray columns: early forms [<180 days after transplantation]; dark grey columns: late forms [≥180 days]).

**Figure 2.** Kaplan-Meier survival curves at week 6 after diagnosis of IPA according to: **a)** timing of diagnosis (log-rank *P*-value = 0.022) and **b)** type of initial antifungal regimen (log-rank *P*-value = 0.002). IPA, invasive pulmonary aspergillosis.

## Supporting Information

Additional Supporting Information may be found in the online version of this article:

**Table S1:** List of participating centers.

**Table S2:** Comparison of baseline clinical characteristics and markers of disease severity between patients initially treated with antifungal combination therapy or other regimens.

**Table S3:** Uni- and multivariate analyses of risk factors predicting all-cause mortality at 12 weeks.

**Table S4:** Uni- and multivariate logistic regression analyses of factors associated with bilateral lung involvement at diagnosis.

**Table S5:** Uni- and multivariate analyses of risk factors predicting graft loss among patients that remained alive at 12 weeks from diagnosis of IPA (n = 68). IPA, invasive pulmonary aspergillosis.

**Figure S1:** Box-and-whisker diagram depicting the median (dot), interquartile range (box), and range (whiskers) for propensity scores for receiving antifungal combination therapy.

**References**


1. Montagna MT, Lovero G, Coretti C, Martinelli D, Delia M, De Giglio O, et al. SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. Infection 2014; 42: 141-151.
2. Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect 2012; 18: 403-408.
3. Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care 2015; 19: 7.
4. Singh N, Husain S; AST Infectious Diseases Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4: 228-241.
5. Gavaldà J, Meije Y, Fortun J, Roilides E, Saliba F, Lortholary O, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 Suppl 7: 27-48.
6. Gavaldà J, Len Ó, San Juan R, Aguado JM, Fortún J, Lumbreras C, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52-59.
7. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G, Invasive Aspergillosis Surveillance Network of the Assistance Publique-Hopitaux de P. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51: 288-296.
8. Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011; 17: 1882-1889.
9. Global observatory on donation and transplantation. 2012 activity data. Available at: http://www.transplant-observatory.org/Pages/Data-Reports.aspx (last accessed: 20 September 2015).
10. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-1111.
11. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: 220-229.
12. Neofytos D, Treadway S, Ostrander D, Alonso CD, Dierberg KL, Nussenblatt V, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis 2013; 15: 233-242.
13. Perez-Saez MJ, Mir M, Montero MM, Crespo M, Montero N, Gomez J, et al. Invasive aspergillosis in kidney transplant recipients: a cohort study. Exp Clin Transplant 2014; 12: 101-105.

14. Neofytos D, Treadway S, Ostrander D, Alonso CD, Dierberg KL, Nussenblatt V, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis 2013; 15: 233-242.
15. Bodro M, Sabe N, Gomila A, Ayats J, Baliellas C, Roca J, et al. Risk factors, clinical characteristics, and outcomes of invasive fungal infections in solid organ transplant recipients. Transplant Proc 2012; 44: 2682-2685.
16. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-1567.
17. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 Suppl 1: S49-58.
18. Abbott KC, Hypolite I, Poropatich RK, Hshieh P, Cruess D, Hawkes CA, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001; 3: 203-211.
19. Santos T, Aguiar B, Santos L, Romaozinho C, Tome R, Macario F, et al. Invasive fungal infections after kidney transplantation: a single-center experience. Transplant Proc 2015; 47: 971-975.
20. Sahin SZ, Akalin H, Ersoy A, Yildiz A, Ocakoglu G, Cetinoglu ED, et al. Invasive fungal infections in renal transplant recipients: epidemiology and risk factors. Mycopathologia 2015; 180: 43-50.
21. Heylen L, Maertens J, Naesens M, Van Wijngaerden E, Lagrou K, Bammens B, et al. Invasive aspergillosis after kidney transplant: case-control study. Clin Infect Dis 2015; 60: 1505-1511.
22. Muñoz P, Valerio M, Palomo J, Giannella M, Yañez JF, Desco M, et al. Targeted antifungal prophylaxis in heart transplant recipients. Transplantation 2013; 96: 664-669.
23. Koller MT, van Delden C, Muller NJ, Baumann P, Lovis C, Marti HP, et al. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol 2013; 28: 347-355.
24. Wojtowicz A, Gresnigt MS, Lecompte T, Bibert S, Manuel O, Joosten LA, et al. IL1B and DEFB1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation. J Infect Dis 2015; 211: 1646-1657.
25. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-89.
26. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112: 2309-2312.

27. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
28. Muñoz P, Vena A, Ceron I, Valerio M, Palomo J, Guinea J, et al. Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis. J Heart Lung Transplant 2014; 33: 1034-1040.
29. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
30. European Expert Group on Renal Transplantation (EBPG), European Renal Association (ERA-EDTA), European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000; 15 Suppl 7: 1-85.
31. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
32. Austin PC, Tu JV. Bootstrap methods for developing predictive models. Am Stat 2004; 58: 131-137.
33. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
34. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 1985; 157: 611-614.
35. Lim C, Seo JB, Park SY, Hwang HJ, Lee HJ, Lee SO, et al. Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation. Clin Radiol 2012; 67: 1179-1186.
36. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-1184.
37. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-1427.
38. Singh N, Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, et al. Performance characteristics of galactomannan and beta-d-glucan in high-risk liver transplant recipients. Transplantation 2015; 99: 2543-2550.
39. Gallagher JC, Dodds Ashley ES, Drew RH, Perfect JR. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 2003; 4: 147-164.

40. Muñoz P, Cerón I, Valerio M, Palomo J, Villa A, Eworo A, et al. Invasive aspergillosis among heart transplant recipients: a 24-year perspective. J Heart Lung Transplant 2014; 33: 278-288.
41. Barchiesi F, Mazzocato S, Mazzanti S, Gesuita R, Skrami E, Fiorentini A, et al. Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. Liver Transpl 2015; 21: 204-212.
42. Bellmann R. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis. Curr Pharm Des 2013; 19: 3629-3647.
43. Domínguez-Gil B, Morales JM. Transplantation in the patient with hepatitis C. Transpl Int 2009; 22: 1117-1131.
44. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919-934.
45. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-750.
46. Rao KV, Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996; 62: 1765-1769.
47. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
48. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 1995; 48: 1495-1450.

**Tables**

**Table 1.** Demographics, pre-transplant and donor-related characteristics and post-transplant events in kidney transplant recipients with early (<180 days) and late IPA (≥180 days).

| Variable | Overall (n = 112) | Early IPA (n = 51) | Late IPA (n = 61) | *P*-value[a] |
|---|---|---|---|---|
| Age at transplantation, years [mean ± SD] | 55.8 ± 14.9 | 57.3 ± 15.6 | 54.6 ± 14.3 | 0.340 |
| Gender (male) [n (%)] | 70 (62.5) | 37 (72.5) | 33 (54.1) | **0.045** |
| Pre-transplant conditions [n (%)] | | | | |
| Diabetes mellitus | 30 (26.8) | 12 (24.0) | 18 (29.5) | 0.516 |
| COPD | 19 (17.0) | 8 (16.3) | 11 (18.3) | 0.784 |
| Pre-transplant corticosteroid therapy [n (%)] | 12 (10.7) | 6 (12.8) | 6 (10.3) | 0.698 |
| BMI at transplantation, Kg/m$^2$ [mean ± SD][b] | 25.1 ± 4.7 | 25.9 ± 5.7 | 24.4 ± 3.6 | 0.163 |
| Previous kidney transplantation [n (%)] | 15 (13.4) | 8 (15.7) | 7 (11.5) | 0.515 |
| Underlying end-stage renal disease [n (%)] | | | | |
| Glomerulonephritis | 26 (23.2) | 11 (21.6) | 15 (24.6) | 0.706 |
| Diabetic nephropathy | 20 (17.9) | 8 (15.7) | 12 (19.7) | 0.583 |
| Policystosis | 18 (16.1) | 9 (17.6) | 9 (14.8) | 0.678 |
| Nephroangiosclerosis | 10 (8.9) | 5 (9.8) | 5 (8.2) | 0.766 |
| Chronic interstitial nephropathy | 7 (6.3) | 4 (7.8) | 3 (4.9) | 0.700 |
| Congenital nephropathy | 4 (3.6) | 1 (2.0) | 3 (4.9) | 0.624 |
| Unknown | 12 (10.7) | 5 (9.8) | 7 (11.5) | 0.776 |
| Other | 15 (13.4) | 8 (15.7) | 7 (11.5) | 0.515 |
| Pre-transplant serostatus [n (%)][c] | | | | |
| HCV | 11 (10.0) | 5 (10.0) | 6 (10.0) | 1.000 |
| HBV surface antigen (HBsAg) | 3 (2.7) | 1 (2.0) | 2 (3.3) | 1.000 |
| CMV | 86 (78.2) | 41 (83.7) | 45 (73.8) | 0.211 |
| Pre-transplant dialysis [n (%)] | 105 (93.8) | 50 (98.0) | 55 (90.2) | 0.124 |
| Dialysis vintage, months [median (IQR)] | 25 (15.5 - 47) | 30 (17 - 57.8) | 23 (15 - 41) | 0.141 |
| Age of donor, years [mean ± SD] | 52.5 ± 15.6 | 56.5 ± 14.0 | 49.0 ± 16.2 | **0.020** |
| Living donor [n (%)][c] | 17 (15.5) | 5 (10.0) | 12 (20.3) | 0.138 |
| Prior antifungal prophylaxis [n (%)] | 2 (4.3) | 2 (9.5) | 0 (0.0) | 0.194 |
| Prior colonization with *Aspergillus* [n (%)] | 5 (4.5) | 1 (2.0) | 4 (6.6) | 0.374 |
| Induction therapy [n (%)][c] | | | | |

| | | | | |
|---|---|---|---|---|
| T-cell depleting agents (ATG or OKT-3) | 29 (26.4) | 13 (26.5) | 16 (26.2) | 0.972 |
| Anti-CD25 monoclonal antibodies | 47 (42.7) | 24 (49.0) | 23 (37.7) | 0.235 |
| None | 36 (32.7) | 13 (26.5) | 23 (37.7) | 0.214 |
| Maintenance immunosuppression at diagnosis including [n (%)][d] | | | | |
| Corticosteroids | 101 (90.9) | 47 (94.0) | 54 (90.0) | 0.507 |
| Daily dose, mg [median (IQR)][e] | 10 (5 - 20) | 17.5 (10 - 21.3) | 6 (5 - 10) | **<0.001** |
| Tacrolimus | 63 (56.8) | 35 (70.0) | 28 (45.9) | **0.011** |
| Cyclosporine | 32 (28.8) | 10 (20.0) | 22 (36.1) | 0.063 |
| MMF / MPA | 80 (72.1) | 36 (72.0) | 44 (72.1) | 0.988 |
| Azathioprine | 7 (6.3) | 2 (4.0) | 5 (8.2) | 0.455 |
| mTOR inhibitor | 13 (11.7) | 3 (6.0) | 10 (16.4) | 0.090 |
| Post-transplant events in the three months prior to diagnosis [n (%)] | | | | |
| Pneumonia | 23 (20.5) | 15 (29.4) | 8 (13.1) | **0.033** |
| Laboratory-confirmed influenza | 4 (3.6) | 1 (2.0) | 3 (4.9) | 0.624 |
| CMV disease | 16 (14.3) | 11 (21.6) | 5 (8.2) | **0.044** |
| Bloodstream infection | 18 (16.1) | 14 (27.5) | 4 (6.6) | **0.003** |
| ICU admission at any time for ≥48 hours | 15 (13.4) | 13 (25.5) | 2 (3.3) | **0.001** |
| Invasive mechanical ventilation | 9 (8.0) | 7 (13.7) | 2 (3.3) | 0.077 |
| *De novo* malignancy | 4 (3.6) | 1 (2.0) | 3 (4.9) | 0.624 |
| Acute graft rejection | 46 (41.1) | 32 (62.7) | 14 (23.0) | **<0.001** |

ATG: antithymocyte globulin; BMI: body mass index; CMV: cytomegalovirus; COPD: chronic obstructive pulmonary disease; HBV: hepatitis B virus; HCV: hepatitis B virus; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis; IQR: interquartile range; MMF / MPA: mofetil mycophenolate / mycophenolate acid; mTOR: mammalian target of rapamycin; SD: standard deviation.

[a] *P*-values refer to comparison between early and late cases of IPA. Significant values are indicated in bold characters.

[b] Data available for 78 patients.

[c] Data available for 110 patients.

[d] Data available for 111 patients.

[e] Prednisone or equivalent corticosteroid.

**Table 2.** Clinical, radiological and microbiological features of IPA cases.

| Variable | Overall (n = 112) | Early IPA (n = 51) | Late IPA (n = 61) | *P*-value[a] |
|---|---|---|---|---|
| Age at diagnosis, years [mean ± SD] | 58.3 ± 14.1 | 57.5 ± 15.6 | 58.9 ± 12.8 | 0.597 |
| EORTC/MSG category [n (%)] | | | | 0.584 |
| Proven diagnosis | 28 (25.0) | 14 (27.5) | 14 (23.0) | |
| Probable diagnosis | 84 (75.0) | 37 (72.5) | 47 (77.0) | |
| Symptoms at presentation [n (%)][b] | | | | |
| Cough | 83 (75.5) | 39 (79.6) | 44 (72.1) | 0.366 |
| Fever | 70 (63.1) | 32 (64.0) | 38 (62.3) | 0.853 |
| Expectoration | 63 (57.3) | 28 (57.1) | 35 (57.4) | 0.980 |
| Pleuritic pain | 42 (37.8) | 20 (40.0) | 22 (36.1) | 0.671 |
| Dyspnea | 25 (22.5) | 10 (20.0) | 15 (24.6) | 0.565 |
| Hemoptysis | 6 (5.4) | 2 (4.0) | 4 (6.6) | 0.688 |
| Septic shock | 3 (2.7) | 0 (0.0) | 3 (4.9) | 0.251 |
| Extrapulmonary involvement [n (%)][c] | 10 (8.9) | 5 (9.8) | 5 (8.2) | 0.766 |
| Findings on thoracic CT scan [n (%)] | | | | |
| Number of lesions [median (IQR)] | 2 (1 - 4) | 2 (1 - 5) | 2 (1 - 4) | 0.970 |
| Maximum diameter, cm [median (IQR)][d] | 2.3 (1.5 - 5.0) | 3.0 (2.0 - 4.5) | 2.0 (1.4 - 5.8) | 0.630 |
| Nodules | 74 (69.8) | 32 (69.6) | 42 (70.0) | 0.961 |
| Cavitation[e] | 32 (29.9) | 12 (25.5) | 20 (33.3) | 0.382 |
| Halo sign[e] | 26 (24.3) | 10 (21.3) | 16 (26.7) | 0.519 |
| Pleural effusion[e] | 44 (41.1) | 23 (48.9) | 21 (35.0) | 0.146 |
| Multilobar involvement | 83 (76.9) | 38 (79.2) | 45 (75.0) | 0.610 |
| Bilateral pulmonary involvement[e] | 68 (62.9) | 30 (63.8) | 38 (63.3) | 0.958 |
| Diagnostic procedures [n (%)][e] | | | | |
| Sputum culture | 33 (30.6) | 17 (34.7) | 16 (27.1) | 0.395 |
| Positive identification | 6 / 33 (18.2) | 3 / 17 (17.6) | 3 / 16 (18.8) | 1.000 |
| Bronchial brush | 22 (20.4) | 9 (18.4) | 13 (22.0) | 0.638 |
| Positive identification | 7 / 22 (31.8) | 4 / 9 (44.4) | 3 / 13 (23.1) | 0.376 |
| BAL | 53 (49.1) | 30 (61.2) | 23 (39.0) | 0.021 |
| Positive identification | 31 / 53 (58.5) | 19 / 30 (63.3) | 12 / 23 (52.2) | 0.414 |
| Lung biopsy | 20 (18.5) | 7 (14.3) | 13 (22.0) | 0.302 |

| | | | | |
|---|---|---|---|---|
| Positive identification | 17 / 20 (85.0) | 7 / 7 (100.0) | 10 / 13 (76.9) | 0.521 |
| Detection of GM in serum sample | 62 (55.4) | 26 (51.0) | 36 (59.0) | 0.394 |
| Positive (index ≥0.5 ODs) | 38 / 62 (61.3) | 15 / 26 (57.7) | 23 / 36 (63.9) | 0.621 |
| Positive (index ≥0.5 ODs) in probable cases | 30 / 50 (60.0) | 11 / 19 (57.9) | 19 / 31 (61.3) | 0.812 |
| Detection of GM in BAL sample | 21 (18.8) | 8 (15.7) | 13 (21.3) | 0.448 |
| Positive (index ≥1.0 ODs) | 12 / 21 (57.1) | 5 / 8 (62.5) | 7 / 13 (53.8) | 1.000 |
| Positive (index ≥1.0 ODs) in probable cases | 9 / 18 (50.0) | 3 / 6 (50.0) | 6 / 12 (50.0) | 1.000 |
| Isolated species [n (%)][f] | | | | 0.862 |
| *Aspergillus fumigatus* | 78 (78.8) | 36 (78.3) | 42 (79.2) | |
| *Aspergillus flavus* | 6 (6.1) | 3 (6.5) | 3 (5.7) | |
| *Aspergillus niger* | 6 (6.1) | 2 (4.3) | 4 (7.5) | |
| Other[g] | 9 (9.1) | 5 (10.9) | 4 (7.5) | |

BAL: bronchoalveolar lavage; CT: computed tomography; EORTC/MSG: European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; GM: galactomannan; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis; IQR: interquartile range; OD: optical density; SD: standard deviation.

[a] *P*-values refer to comparison between early and late cases of IPA.

[b] Data available for 111 patients.

[c] Included involvement of central nervous system (3 cases), sinus (3 cases), skin (3 cases), liver (2 cases) and endocardium (one case).

[d] Data available for 59 patients.

[e] Data available for 108 patients.

[f] Percentages calculated on the 99 cases (72 probable IPA and 27 proven) with *Aspergillus* speciation.

[g] Includes *A. terreus* (n = 4), *A. calidoustus* (n = 3), *A. nidulans* (n = 1) and *Aspergillus* section *Flavipedes* (n = 1).

**Table 3.** Therapeutic approaches in patients that received any antifungal treatment (n = 109).

| Variable | N (%) |
|---|---|
| Initial antifungal therapy[a] | |
| Monotherapy | 71 (65.1) |
| Amphotericin B | |
| L-AmB | 10 (9.2) |
| AmB-D | 5 (4.6) |
| AmB-LC | 1 (0.9) |
| AmB-D plus AmB-LC | 1 (0.9) |
| Triazoles | |
| Voriconazole | 47 (43.1) |
| Itraconazole | 3 (2.8) |
| Echinocandins | |
| Caspofungin | 2 (1.8) |
| Anidulafungin | 2 (1.8) |
| Combination therapy[b] | 22 (20.1) |
| Voriconazole plus echinocandin | 10 (9.2) |
| Amphotericin B plus echinocandin | 5 (4.6) |
| Amphotericin B plus triazole | 4 (3.7) |
| Voriconazole plus echinocandin plus amphotericin B | 3 (2.8) |
| Sequential therapy[c] | 16 (14.7) |
| Amphotericin B followed by triazole | 6 (5.5) |
| Echinocandin followed by triazole | 6 (5.5) |
| Voriconazole followed by amphotericin B | 2 (1.8) |
| Amphotericin B followed by echinocandin | 1 (0.9) |
| Voriconazole followed by echinocandin | 1 (0.9) |
| Adjuvant therapy | |
| G-CSF | 7 (6.4) |
| Surgery | 6 (5.5) |
| Reduction in overall immunosuppression[d] | 80 (80.0) |
| Reduction by ≥50% in daily corticosteroid dose[e] | 21 (28.0) |
| Requirement for ICU admission | 22 (20.2) |

| | |
|---|---|
| Requirement for acute renal replacement therapy at diagnosis of IPA[f] | 34 (31.2) |

AmB-D: amphotericin B deoxycholate; AmB-LC: amphotericin B lipid complex; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis; G-CSF: granulocyte-colony stimulating factor; IQR: interquartile range; L-AmB: liposomal amphotericin B; SD: standard deviation.

[a] Refers to that administered during the first two weeks of therapy.

[b] Refers to the concomitant administration for ≥72 hours of two or more active antifungal drugs within the first two weeks of therapy.

[c] Refers to the consecutive administration of two or more active antifungal drugs within the first two weeks of therapy (an overlap period of less than 72 hours was allowed).

[d] Within the first month after diagnosis of IPA. Data available for 100 patients.

[e] Within the first month after diagnosis of IPA. Data available for 75 patients.

[f] Between one month before and one month after the diagnosis of IPA.

**Table 4.** Uni- and multivariate analyses of risk factors predicting all-cause mortality at 6 weeks from the diagnosis of IPA.

| Variable | Survivors (n = 77) | Non-survivors (n = 35) | *P*-value[a] | Univariate | | | Multivariate | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | HR | 95% CI | *P*-value | HR | 95% CI | *P*-value |
| Age at diagnosis, years [mean ± SD] | 58.6 ± 13.7 | 57.6 ± 15.1 | 0.720 | | | | | | |
| Male gender [n (%)] | 49 (63.6) | 21 (60.0) | 0.713 | | | | | | |
| Diagnosis in 2007-2013 compared to 2000-2006 [n (%)] | 62 (80.5) | 22 (62.9) | **0.045** | 0.50 | 0.25 - 0.99 | 0.048 | - | - | - |
| Pre-transplant diabetes mellitus [n (%)] | 21 (27.6) | 9 (25.7) | 0.833 | | | | | | |
| Pre-transplant COPD [n (%)] | 12 (16.2) | 7 (20.0) | 0.627 | | | | | | |
| Positive HCV serostatus | 6 (7.9) | 5 (14.7) | 0.310 | | | | | | |
| Previous kidney transplantation [n (%)] | 10 (13.0) | 5 (14.3) | 1.000 | | | | | | |
| Living donor [n (%)] | 14 (18.4) | 3 (9.1) | 0.217 | | | | | | |
| Prior CMV disease [n (%)][b] | 9 (11.7) | 7 (20.0) | 0.244 | | | | | | |
| Prior ICU admission at any time for ≥48 hours [n (%)][b] | 9 (11.7) | 6 (17.1) | 0.550 | | | | | | |
| Prior invasive mechanical ventilation [n (%)][b] | 3 (3.9) | 6 (17.1) | **0.026** | 2.79 | 1.15 - 6.75 | 0.023 | - | - | - |
| Prior acute graft rejection [n (%)][b] | 28 (36.4) | 18 (51.4) | 0.133 | | | | | | |
| Proven EORTC/MSG category [n (%)] | 23 (29.9) | 5 (14.3) | 0.077 | | | | | | |
| Early diagnosis (<180 days after transplant) | 29 (37.7) | 22 (62.9) | **0.013** | 2.46 | 1.24 - 4.88 | 0.010 | 2.29 | 1.10 - 4.79 | 0.027 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| compared to late (≥180 days) [n (%)] | | | | | | | | | |
| Fever at presentation [n (%)][c] | 44 (57.9) | 26 (74.3) | 0.096 | | | | | | |
| Cough at presentation [n (%)][c] | 58 (77.3) | 25 (71.4) | 0.503 | | | | | | |
| Dyspnea at presentation [n (%)][c] | 17 (22.4) | 8 (22.9) | 0.954 | | | | | | |
| Extrapulmonary involvement [n (%)] | 9 (11.7) | 1 (2.9) | 0.168 | | | | | | |
| Number of lesions [median (IQR)] | 2 (1 - 4) | 3 (1 - 4.8) | 0.678 | | | | | | |
| Halo sign [n (%)][d] | 21 (27.3) | 5 (16.7) | 0.251 | | | | | | |
| Cavitation [n (%)][d] | 23 (29.9) | 9 (30.0) | 0.989 | | | | | | |
| Plural effusion [n (%)][d] | 28 (36.4) | 16 (53.3) | 0.109 | | | | | | |
| Multilobar involvement [n (%)][d] | 56 (72.7) | 27 (87.1) | 0.109 | | | | | | |
| Bilateral pulmonary involvement [n (%)] | 43 (56.6) | 25 (80.6) | **0.019** | 2.64 | 1.08 - 6.44 | 0.033 | 3.00 | 1.22 - 7.39 | 0.017 |
| Serum GM index (ODs) [median (IQR)][e] | 0.5 (0 - 1) | 1.1 (0.5 - 3.4) | **0.024** | | | | | | |
| BAL GM index (ODs) [median (IQR)][f] | 1 (0 - 3.1) | 6.5 (1.9 - 7.8) | **0.014** | | | | | | |
| Initial antifungal therapy [n (%)][g] | | | | | | | | | |
| Amphotericin B-based regimen | 13 (16.9) | 6 (18.8) | 0.815 | | | | | | |
| Voriconazole-based regimen | 47 (61.0) | 9 (28.1) | **0.002** | 0.32 | 0.15 - 0.68 | 0.003 | 0.34 | 0.15 - 0.74 | 0.007 |
| Echinocandin-based regimen | 2 (2.6) | 4 (12.5) | 0.060 | | | | | | |
| Combination regimen | 10 (13.0) | 12 (37.5) | **0.004** | 2.60 | 1.27 - 5.34 | 0.009 | - | - | - |
| Interval from diagnosis to initiation of treatment <48 hours [n (%)] | 58 (75.3) | 26 (81.2) | 0.503 | | | | | | |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Surgery [n (%)][g] | 6 (7.8) | 0 (0.0) | 0.177 | | | | | | |
| Reduction by ≥50% in corticosteroid dose [n (%)][h] | 19 (28.8) | 2 (22.2) | 1.000 | | | | | | |
| Requirement for ICU admission [n (%)][g] | 11 (14.3) | 11 (31.4) | **0.017** | 2.06 | 1.01 - 4.20 | 0.048 | - | - | - |
| Requirement for acute renal replacement therapy at diagnosis of IPA [n (%)][g,i] | 17 (22.1) | 17 (53.1) | **0.001** | 2.47 | 1.27 - 4.81 | 0.008 | - | - | - |

BAL: bronchoalveolar lavage; CI: confidence interval; CMV: cytomegalovirus; COPD: chronic obstructive pulmonary disease; EORTC/MSG: European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; GM: galactomannan; HCV: hepatitis C virus; HR: hazard ratio; ICU: intensive care unit; IPA: invasive pulmonary aspergillosis; IQR: interquartile range; OD: optical density; SD: standard deviation.

[a] Significant *P*-values at the univariate level are indicated in bold characters. Unless otherwise specified, these variables were entered into the Cox regression model.

[b] Within the three months prior to diagnosis of IPA.

[c] Data available for 111 patients.

[d] Data available for 108 patients.

[e] Data available for 45 patients. This variable was not included into the model due to the low number of patients in which the assay was tested.

[f] Data available for 17 patients. This variable was not included into the model due to the low number of patients in which the assay was tested.

[g] Percentages calculated on the 109 patients that received any antifungal treatment.

[h] Within the first month after diagnosis of IPA. Data available for 75 patients.

[i] Between one month before and one month after the diagnosis of IPA.

**Figure 1.**

ajt_13837_f1.pdf